Somewhat Positive Media Coverage Somewhat Unlikely to Impact Neurocrine Biosciences (NBIX) Share Price

Media headlines about Neurocrine Biosciences (NASDAQ:NBIX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.0619895996556 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ:NBIX traded down $3.06 during mid-day trading on Friday, reaching $76.85. The company’s stock had a trading volume of 587,905 shares, compared to its average volume of 887,076. The company has a current ratio of 10.20, a quick ratio of 10.20 and a debt-to-equity ratio of 0.99. Neurocrine Biosciences has a twelve month low of $39.50 and a twelve month high of $92.98. The firm has a market cap of $7,139.21, a price-to-earnings ratio of -47.44 and a beta of 0.29.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The business had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter last year, the firm posted ($0.51) earnings per share. research analysts forecast that Neurocrine Biosciences will post -0.23 earnings per share for the current fiscal year.

A number of analysts recently commented on NBIX shares. Jefferies Group increased their price objective on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Oppenheimer set a $85.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Leerink Swann raised their price target on Neurocrine Biosciences from $90.00 to $96.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 20th. JPMorgan Chase raised their price target on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. Finally, Barclays reissued an “overweight” rating and issued a $100.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, February 14th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $95.23.

In other news, insider Haig P. Bozigian sold 1,625 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total value of $128,570.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Haig P. Bozigian sold 75,873 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $90.00, for a total value of $6,828,570.00. Following the completion of the transaction, the insider now owns 18,041 shares in the company, valued at $1,623,690. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 367,136 shares of company stock worth $30,001,192. Company insiders own 4.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3336591/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-neurocrine-biosciences-nbix-share-price.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pioneer Energy Services  Stock Price Up 6.7%
Pioneer Energy Services Stock Price Up 6.7%
Baozun  Trading 5.9% Higher
Baozun Trading 5.9% Higher
Nucor  Posts  Earnings Results, Misses Estimates By $0.06 EPS
Nucor Posts Earnings Results, Misses Estimates By $0.06 EPS
Head to Head Survey: Goldcorp  and Its Competitors
Head to Head Survey: Goldcorp and Its Competitors
K2M Group Holdings  Receives Consensus Rating of “Buy” from Brokerages
K2M Group Holdings Receives Consensus Rating of “Buy” from Brokerages
Contrasting Integra lifesciences  & Bio-Rad Laboratories
Contrasting Integra lifesciences & Bio-Rad Laboratories


Leave a Reply

© 2006-2018 Ticker Report. Google+.